Johns Hopkins Medicine researchers have studied the reaction of nearly 200 solid organ transplant recipients to their first COVID-19 vaccine shot. The findings, they say, suggest that the Moderna and Pfizer/BioNTech mRNA vaccines can be safely given to...
By Mike Pears and Joel Beevers, Patent Attorneys at Potter Clarkson
January 1, 2021 marked the UK’s official separation from the EU and with that has come a raft of changes to how the nation will now do business with the rest of the world.
EU pharma industry representatives have expressed concern that the recently enacted EU export transparency mechanism could risk production delays or jeopardize the supply of COVID-19 vaccines in Europe.
CureVac aims to bring together expertise from both its own company and other stakeholders to provide ‘broader and faster protection against current and future viral threats’: through collaborations with the UK Government, Bayer and GSK.
J&J pledges to start shipping doses of its COVID-19 vaccine in the US as soon as Emergency Use Authorization (EUA) is received from the Food and Drug Administration, while it plans to apply for Conditional Marketing Authorization in the EU in the...
Novavax has started sharing early clinical data for its COVID-19 vaccine with health authorities in the UK, EU, US and Canada as it starts the rolling review process in these jurisdictions.
South Africa is halting the use of the Oxford University-AstraZeneca COVID-19 vaccine in its vaccination campaign following the release of trial data showing the jab offered limited protection against mild to moderate infection caused by the country’s...
A single-dose intranasal influenza vaccine is safe and produces a durable immune response, according to a Phase 1 study published in the Journal of Clinical Investigation this week.
Illumina, a DNA sequencing and array-based technology specialist, is supporting the Belgian Society of Medical Oncology (BSMO) in a pilot study examining the use of comprehensive genomic profiling (CGP) in 864 patients with advanced metastatic cancer....
An Oxford University trial, a world first, is looking at whether inoculating volunteers with doses of different combinations of two currently approved COVID-19 vaccines is effective.
UK based pharma group, GlaxoSmithKline, and German biotech, CureVac, have struck a €150m (US$180m) deal to jointly develop next generation mRNA vaccines for COVID-19; the goal is to address multi-variants with one vaccine.
Pfizer and BioNTech now plan to manufacture two billion doses of their mRNA COVID-19 vaccine in 2021: up from the previous goal of 1.3 billion doses. Pfizer is forecasting $15bn in sales from the vaccine this year.
